arrow
E

Emmanuel S. Antonarakis

university of minnesota
H指数:82
被引数:3.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Molecular and clinical correlates of high FOLH1 (PSMA) RNA expression in primary and metastatic prostate cancer

FOLH1 (PSMA) RNA在原发性和转移性前列腺癌中高表达的分 子与临床相关性

2025-11-110
OA
HLA class I expression shapes the tumor immune microenvironment and influences prognosis in prostate cancer

HLA class I expression塑造前列腺癌的肿瘤免疫微环境并影响其预后

2025-10-250
OA
CREB5 promotes tumorigenicity and upregulates druggable cell surface modalities in basal-like breast cancer

CREB5促进基底样乳腺癌的致瘤性,并上调可靶向的细胞表面模式识别分子。

2025-08-060
OAAI
Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer

KEYLYNK-010研究中患者报告结局:帕博利珠单抗联合奥拉帕利与阿比特龙或恩扎卢胺治疗生物标志物未筛选、既往接受过治疗的转移性去势抵抗性前列腺癌患者

2025-07-190
OAAI
Inferred clonal hematopoiesis from tumor DNA sequencing among men with prostate cancer: correlation with somatic tumor alterations and outcomes

从前列腺癌患者肿瘤DNA测序中推断出的克隆性造血:与肿瘤体细胞改变及预后的相关性

2025-04-220
OA
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes
2025-02-070
PRE
Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024

对患有生物化学复发和晚期前列腺癌的男性实施循证策略: 来自美国前列腺癌会议2024的共识建议

CANCER
IF5.1
2024-12-010
PRE